NRx Pharmaceuticals报告潜在的收购和融资协议

2024-08-26 20:06

NRx Pharmaceuticals (NASDAQ:NRXP) subsidiary, HOPE Therapeutics, Monday reported the signing of a non-binding term sheet for non-dilutive, nonconvertible debt acquisition funding of its first interventional psychiatry clinics (ketamine clinic acquisitions).
In addition to the currently signed non-binding term sheet, the company has been offered non-binding lending commitments it believes are sufficient to assemble/acquire a network of operational clinics with revenues exceeding $100 million.
The company anticipates potential operations in the United States, France, and the United Kingdom.
The non-dilutive acquisition funding announced on Monday is in addition to the over $60 million in potential equity funding previously offered upon public listing of HOPE Therapeutics shares on a public exchange.
NRXP +4.33% premarket to $2.17.
Source: Press Release

More on NRx Pharmaceuticals